Market research
3MT.F Magenta Therapeutics, Inc
F EUR Not available
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 15.71
- Dividend yield
- 0.0%
- Beta
- 2.12
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 15.71
- Dividend yield
- 0.0%
- Beta
- 2.12
About
About Magenta Therapeutics, Inc
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs and delivers novel monoclonal antibodies. It develops monoclonal antibodies and complement therapeutics to deliver transformative medicines for patients with rare diseases. Dianthus Therapeutics, Inc. was incorporated in 2019 and is based in Waltham, Massachusetts, with an additional office in New York, New York.
Research context
Magenta Therapeutics, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
0 comments
Sign in to join the 3MT.F discussion.
No comments yet
Start a focused discussion about 3MT.F.